5.59

3.62% -0.21

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $5.59, with a volume of 2.83M. It is down -3.62% in the last 24 hours and up +32.15% over the past month. Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Previous Close:

$5.80

Open:

$5.88

24h Volume:

2.83M

Relative Volume:

1.15

Market Cap:

$444.37M

Revenue:

$409.00K

Net Income/Loss:

$-101.35M

P/E Ratio:

-3.4085

EPS:

-1.64

Net Cash Flow:

$-71.49M

1W Performance:

-3.12%

1M Performance:

+32.15%

6M Performance:

-27.21%

1Y Performance:

-27.59%

1-Day Range:

$5.52

$6.05

1-Week Range:

$4.95

$6.05

52-Week Range:

$3.553

$11.16

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	5.59	444.37M	409.00K	-101.35M	-71.49M	-1.64
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

01:15 AM

Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire

01:15 AM

May 09, 2025

FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire

May 09, 2025

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - Nasdaq

May 09, 2025

May 08, 2025

Altimmune's (ALT) Pemvidutide Shows Promising Results in Liver Health Study | ALT Stock News - GuruFocus

May 08, 2025

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ | ALT Stock News - GuruFocus

May 08, 2025

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - The Manila Times

May 08, 2025

Altimmune Presents Promising Analyses of Pemvidutide's Efficacy in MASH Treatment at EASL 2025 - Nasdaq

May 08, 2025

May 07, 2025

Altimmune at The Citizens JMP Life Sciences Conference: Pembidutide’s Promise - Investing.com

May 07, 2025

May 06, 2025

Altimmune to Report First Quarter 2025 Financial Results and Pro - GuruFocus

May 06, 2025

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - The Manila Times

May 06, 2025

Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 - Nasdaq

May 06, 2025

Clinical-Stage Biotech Altimmune Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

May 06, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - The Manila Times

May 01, 2025

Altimmune, Inc. to Showcase Novel MASH Resolution Index Data for Pemvidutide at EASL International Liver Congress™ 2025 - Nasdaq

May 01, 2025

Apr 30, 2025

Altimmune to Participate in the Citizens Life Sciences Conferenc - GuruFocus

Apr 30, 2025

Altimmune to Participate in the Citizens Life Sciences Conference - The Manila Times

Apr 30, 2025

Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance

Apr 30, 2025

Apr 26, 2025